Gilead & PAHO Partner To Accelerate Access To Twice-Yearly Lenacapavir Across Latin America & Caribbean

Sept. 15 (Reuters) - Gilead Sciences, Inc. (GILD.O):

• Gilead and PAHO announce partnership to accelerate access to twice-yearly lenacapavir for HIV prevention across Latin America & Caribbean
• The agreement establishes a regional pathway through the Pan American Health Organization's regional revolving funds
• Gilead will continue exploring opportunities to work with PAHO to support country readiness and scale-up of long-acting HIV prevention access
• Gilead is also exploring opportunities with the Brazilian Health Ministry to advance the ministry’s goal of enabling local production of lenacapavir